Mark L. Baum

Mark L. Baum is the Founder, Chairman, and CEO of Harrow, a leading North American ophthalmic pharmaceutical company established in December 2011, providing a comprehensive portfolio of eyecare medications. Baum also serves as a Board Member for the Ophthalmology Foundation, which focuses on enhancing ophthalmic education in under-resourced regions. In April 2014, Baum founded ImprimisRx, a prominent provider of compounded ophthalmic prescription medications. Additionally, Baum is the Founder and Chairman of Melt Pharmaceuticals, dedicated to innovative sedation solutions, and previously founded Surface Ophthalmics and Eton Pharmaceuticals. Baum participated in the Nashville Health Care Council's Fellows program in early 2020 and served as a Senior Advisory Consultant for Curology from January 2015 to July 2017. Education includes a Juris Doctorate from California Western School of Law and studies at The University of Texas at Arlington.